Liver-Directed Therapy in Metastatic Colorectal Cancer

Ana Wilson, Sean Ronnekliev-Kelly, Megan Winner, Timothy M. Pawlik

Research output: Contribution to journalArticlepeer-review


Approximately 50–70 % of patients with colorectal cancer ultimately develop colorectal liver metastases. Determining which patients may benefit from aggressive treatment has historically been achieved through clinical predictive models. However, factors such as radiographic response to neoadjuvant therapy should also be taken into consideration. Recently, molecular markers have emerged as an adjunct to clinical-pathologic factors and provide a surrogate for tumor biology. With improved understanding of tumor biology, the likelihood of recurrence can be better predicted. However, when feasible, the best chance for cure entails surgical resection as a part of multimodal therapy, and select patients can achieve prolonged median survival. Alternatively, ablation techniques may be used in conjunction with surgery or as isolated therapy in patients who are not candidates for surgical resection. Transarterial therapy may also provide clinical benefit in certain patient subsets with unresectable disease. These strategies have allowed for a more tailored approach to patients with colorectal liver metastases.

Original languageEnglish (US)
Pages (from-to)1-14
Number of pages14
JournalCurrent Colorectal Cancer Reports
StateAccepted/In press - Mar 1 2016


  • Colorectal
  • Liver metastasis
  • Personalized
  • Therapy

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology
  • Hepatology


Dive into the research topics of 'Liver-Directed Therapy in Metastatic Colorectal Cancer'. Together they form a unique fingerprint.

Cite this